Sigachi begins construction work for MCC capacity expansion at Dahej
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
NEIAFMR to be developed as the national hub for folk medicine
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The company allocated €56 million to research and development for next-generation line solutions
The facility is expected to become operational by FY2028-29
The company’s EBITDA margin remained resilient above 20%
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Subscribe To Our Newsletter & Stay Updated